Liver Disorders
An introduction to touchHEPATOLOGY
Many liver diseases are associated with endocrine disorders, including nonalcoholic fatty liver disease (NAFLD), autoimmune hepatitis and primary biliary cirrhosis. NAFLD is the most common liver disorder worldwide and its rising prevalence mirrors that of obesity and type 2 diabetes. Thyroid disorders are often associated with hepatic alterations. Chronic liver disease can impair menstruation and fertility. In addition, patients with diabetes have a higher prevalence of significant liver fibrosis and enhanced risk of disease progression to cirrhosis and hepatocellular carcinoma. Management of these disorders should consider the relationship between the liver and the endocrine system, in order to address all manifestations and complications.
Browse video highlights and short articles from the conference hub, providing insights into the latest updates from major conferences and peer-reviewed articles from the journal portfolio. This is complemented by a range of educational activities from our expert faculty, with patient outcomes at the forefront.
Our supporting partners do not constitute an endorsement of the content on this page.
Welcome to the summer 2026 issue of touchREVIEWS in Endocrinology. In this issue, we bring together articles that reflect the evolving complexity of endocrine and metabolic disease, while highlighting the growing importance of patient-centred care, translational science and interdisciplinary management. We ...
The UK National Screening Committee has opened a public consultation on universal newborn screening for biliary atresia. Although early detection improves outcomes, current evidence on dried blood spot biomarkers and stool colour cards remains insufficient for population screening. Stakeholders are invited to submit evidence by 20 May 2026.
February is Rare Liver Diseases Month, bringing global attention to policy, education and advocacy needs surrounding rare liver conditions. During this month, the Global Liver Institute leads its annual #RareAware campaign to highlight the importance of early detection and access to care. With more than 100 rare liver diseases often going unrecognised, greater awareness helps patients receive timely support and empowers families to make informed decisions and advocate confidently for their care.
The global prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) has increased over the past three decades and is estimated to be 30% as of 2022.1Â As an indication of disease burden, MASLD-related liver transplantation has already surpassed many other aetiologies as ...
The American Association for the Study of Liver Diseases (AASLD) has released a significant update to its practice guidance on metabolic dysfunction–associated steatotic liver disease (MASLD), formally incorporating semaglutide as a recommended therapeutic option for adults with MASH and F2–F3 fibrosis. This expansion comes following the August 2025 accelerated FDA approval of semaglutide for MASH with moderate-to-advanced fibrosis, following positive interim Phase 3 findings.
The AASLD 2025 Liver Meeting® (7–11 November, Washington, D.C., USA) delivered a breadth of early- and late-phase data across metabolic liver disease, cholestatic conditions, liver failure, and rare liver diseases. This year’s findings reflected a rapidly evolving therapeutic landscape, with meaningful progress in mechanistic understanding, emerging signals of disease modification, and increasing momentum toward more precise, combination-oriented strategies across multiple liver conditions.
Welcome to the latest edition of touchREVIEWS in Endocrinology, which features a diverse selection of editorials, reviews and original research articles that highlight both the progress and the ongoing challenges in translating pathophysiological insight into patient-centred care. We begin with ...
Fatty liver is the largest liver disease globally and has become a leading cause of liver cirrhosis and end-stage liver disease. Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic steatohepatitis (NASH), affects about one-third of the adult population ...
Dr Thinzar Min discusses how the Enhanced Liver Fibrosis (ELF) test could help detect liver fibrosis and assess cardiovascular risk in people with type 2 diabetes.
As touchENDOCRINOLOGY approaches 22 years of providing education for busy endocrinologists, we are looking to the future—and it certainly looks bright! This year, we are celebrating our inaugural touchENDOCRINOLOGY Future Leaders to recognize the outstanding talent that has entered our ...
This Q&A with Dr Paul Brennan offers a practical guide to the diagnosis and management of metabolic dysfunction-associated steatohepatitis (MASH). Covering key risk factors, non-invasive diagnostic tools, lifestyle strategies, and emerging therapies, it provides clinicians with clear approaches to early detection and comprehensive patient care.
Prof Mak, a leading clinician-scientist in hepatology, discusses her inspirations, groundbreaking research on liver diseases, and commitment to patient-centered care. She reflects on milestones in her career and shares insights into emerging therapies and trends transforming the field.
Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more effective healthcare culture.
What if your medical degree could launch more than a clinical career? In this candid and compelling read, Dr Jon Edelson shares his lessons for early-career clinicians ready to think beyond the bedside and explore the business of medicine.
At touchENDOCRINOLOGY, we’re proud to support Global Fatty Liver Day on 12  June, an important initiative led by the Global Liver Institute. This annual campaign highlights the growing urgency of fatty liver disease, especially in its advanced stages, and calls on both healthcare professionals and the public to take meaningful action through education, early detection and healthy lifestyle choices.
We are pleased to present the latest issue of touchREVIEWS in Endocrinology, which offers a timely and thoughtprovoking collection of articles that reflect both the continuity and evolution of diabetes and metabolic disease research. In an era where technology, public ...
Article Highlights This study aims to find an effective and affordable biomarker panel for early non-alcoholic fatty liver disease (NAFLD) detection in Indian women with morbid obesity, given the rising prevalence of NAFLD and limited accessibility of ultrasound sonography (USG) ...
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
